Crossover pilot trial evaluates safety and axial elongation of non-refractive spectacle lenses in myopic children, indicating feasibility for non-defocus myopia control.
Optical myopia-control strategies predominantly introduce competing defocus, extend depth of focus, or modify retinal contrast [ 1 ]. A single-vision spectacle lens utilising non-refractive, light-absorbing opaque features to alter spatiotemporal retinal luminance during natural eye movement without defocus, blur, or scatter was developed [ 2 ]. Visual performance in adults was superior to a competing defocus design [ 3 ]. In-vivo myopia efficacy is unknown, and experimental evidence that partial occlusion could potentiate myopiagenesis [ 4 ], underpinning the need for paediatric safety data. A contact-lens counterpart demonstrated safety in a small pilot [ 5 ]; however, spectacle delivery is preferable for younger children. This 14-month, three-phase, within-participant crossover pilot assesses safety (primary) and axial elongation (secondary) in myopic children.
No takes yet. Share an insight, caveat, or question.
Bakaraju et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: